Serum antibodies to cross‐reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease

Mæland, Johan A.; Wedege, Elisabeth

doi:10.1111/j.1699-0463.1989.tb00477.x

Cited by 36 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the LOS L11-specific ELISA, we observed that anti-LOS IgG levels increased significantly in patients during early convalescent phase (Table 2), in line with a previous study in Egyptian MenA patients (49) and in patients with MenB and MenC disease (13,22,33,43,57). Although anti-LOS L11 IgG increased significantly during disease and remained elevated in the late convalescent phase, the GMCs in acute-phase or lateconvalescent-phase sera were not statistically different from that found in Ethiopian control sera.…”

Section: Discussionsupporting

confidence: 90%

Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A Meningococci

Norheim

Aseffa

Yassin

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

Dissecting the specificities of human antibody responses following disease caused by serogroup A meningococci may be important for the development of improved vaccines. We performed a study of Ethiopian patients during outbreaks in 2002 and 2003. Sera were obtained from 71 patients with meningitis caused by bacteria of sequence type 7, as confirmed by PCR or culture, and from 113 Ethiopian controls. Antibody specificities were analyzed by immunoblotting (IB) against outer membrane antigen extracts of a reference strain and of the patients' own isolates and by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) levels against lipooligosaccharide (LOS) L11 and the proteins NadA and NspA. IB revealed that the main antigens targeted were the proteins PorA, PorB, RmpM, and Opa/OpcA, as well as LOS. MenA disease induced significant increases in IgG against LOS L11 and NadA. The IgG levels against LOS remained elevated following disease, whereas the IgG anti-NadA levels returned to acute-phase levels in the late convalescent phase. Among adults, the anti-LOS IgG levels were similar in acute-phase patient sera as in control sera, whereas anti-NadA IgG levels were significantly higher in acute-phase sera than in controls. The IgG antibody levels against LOS and NadA correlated moderately but significantly with serum bactericidal activity against MenA strains. Future studies on immune response during MenA disease should take into account the high levels of anti-MenA polysaccharide IgG commonly found in the population and seek to clarify the role of antibodies against subcapsular antigens in protection against MenA disease.

show abstract

Section: Discussionsupporting

confidence: 90%

Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A Meningococci

Norheim

Aseffa

Yassin

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…I). No binding to the class 3 porin protein was observed which was in agreement with a previous study of patient sera (18). Thus, the antibody responses observed on immunoblots correlated well with those measured by ELISA (Table 3).…”

Section: Immunoblotting Studiessupporting

confidence: 91%

IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination

Sjursen

Wedege²,

Rosenqvist³

et al. 1990

APMIS

Self Cite

View full text Add to dashboard Cite

IgG and IgG subclass antibodies to the outer membrane antigens from Neisseria meningitidis (serogroup B., serotype 15:P1.16) were quantitated by an enzyme‐linked immunosorbent assay (ELISA) in sera from 40 patients with group B:15:P1.16 meningococcal disease and 24 volunteers immunized with a serotype 15:P1.16 outer membrane vesicle vaccine. A second injection was given 6 weeks after the first immunization. Patient sera obtained two and six weeks after onset of the disease had significantly higher levels of total IgG, IgG1, IgG2, and IgG3 antibodies to the outer membrane antigens than acute sera, convalescent sera from patients with systemic non‐meningococcal bacterial infections and sera from healthy controls. The levels of total IgG and IgG 1 remained high one and three years later. Sera from the vaccinees showed high levels of total IgG and IgG 1 6, 12 and 26 weeks after the first immunization and high levels of IgG3 6 weeks after the second immunization. No increase of IgG2 or IgG4 levels was observed in the postimmunization sera. Immunoblotting of three convalescent sera demonstrated individual patterns of IgG subclass binding to various outer membrane antigens with most distinct binding of IgG 1 and IgG3 antibodies to the class 1 protein, the H.8 lipoprotein and the lipopolysaccharide. Since IgGl and IgG3 are the most effective antibodies for complement activation and phagocytosis, group B meningococcal disease and immunization with the serotype 15:P1.16 outer membrane vesicle vaccine stimulate production of those IgG subclasses which have the strongest opsonic and bactericidal activity.

show abstract

“…To our knowledge, this is the first attempt to quantitate the human antibody response to the VRs of the class 1 protein by subtype-specific antigens free of other meningococcal components. Previously, several investigators have studied the presence of anti-class 1 protein antibodies in human sera, by immunoblotting, [15][16][17][35][36][37] gel irnrnunoradioas~ay,~* inhibition studies with murine MAbs39-41 and EIA with purified P1.7,l 6.34…”

Section: Discussionmentioning

confidence: 99%

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease

Idänpään‐Heikkilä

Høiby²,

Chattopadhyay

et al. 1995

Journal of Medical Microbiology

View full text Add to dashboard Cite

Summary. Antibodies to the meningococcal serosubtype-specific P1.7,16 protein and its variable regions (VR) were analysed in 28 convalescent sera drawn 8-36 months after systemic meningococcal disease by immunoblotting and enzyme immunoassay (EIA) methods. EIA antigens were the meningococcal P1.7,16 protein, produced in Bacillus subtilis, and peptides covering its VRl (P1.7 region) and VR2 (P1.16 region) inserted into a bacterial penicillinase protein. In the immunoblotting method, three meningococcal reference strains were used; they expressed either the P1.7,16 protein, or only its VR1 or VR2 epitopes in their class 1 proteins. Both methods showed a strong IgG response in four sera to P1.7,16 and VR2, but not to VR1; 18 sera had no or weak anti-class 1 protein activity. The six remaining sera were positive only on blots. The VR2-specific sera had 30-fold higher bactericidal activity than those with negligible P1.7,16 responses. Previous vaccination of the patients with a B : 1 5 : P1.7,16 meningococcal vaccine was associated with a strong anti-P 1.7,16 and anti-VR2 booster response that declined with time. The subtype-specific antibody activity in some sera indicated colonisation after disease by meningococci with class 1 proteins different from the strain that had caused disease.

show abstract

Serum antibodies to cross‐reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease

Cited by 36 publications

References 25 publications

Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A Meningococci

Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A Meningococci

IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease

Contact Info

Product

Resources

About